Compare VTYX & CGBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VTYX | CGBD |
|---|---|---|
| Founded | 2018 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 990.9M | 913.5M |
| IPO Year | 2021 | N/A |
| Metric | VTYX | CGBD |
|---|---|---|
| Price | $13.99 | $10.75 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 7 | 7 |
| Target Price | $13.50 | $13.50 |
| AVG Volume (30 Days) | ★ 3.8M | 745.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 15.19% |
| EPS Growth | ★ 40.30 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $3.70 |
| Revenue Next Year | N/A | $1.07 |
| P/E Ratio | ★ N/A | $10.36 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.90 | $10.64 |
| 52 Week High | $15.34 | $17.33 |
| Indicator | VTYX | CGBD |
|---|---|---|
| Relative Strength Index (RSI) | 72.58 | 33.84 |
| Support Level | $13.89 | N/A |
| Resistance Level | $14.07 | $13.06 |
| Average True Range (ATR) | 0.03 | 0.33 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 88.89 | 10.71 |
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.